Clovis Oncology's cancer drug Rubraca succeeds in key study

Investors sentiment decreased to 1.03 in Q4 2016. It is negative, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings.

Endurant Capital Management LP raised its position in shares of Clovis Oncology, Inc. Manufacturers Life Insur The holds 21,957 shares or 0% of its portfolio. Jpmorgan Chase And Co reported 170,388 shares. Geode Cap Management Ltd holds 290,450 shares. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since June 19, 2016 and is uptrending. Citigroup reported 247,642 shares. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 100 shares in the last quarter. Proshare Ltd Liability invested in 0.02% or 30,597 shares. Additionally, the stock's volume is skyrocketing with almost 11 million shares already sold today. Td Asset Mngmt accumulated 17,226 shares or 0% of the stock.

EAM Investors LLC acquired a new stake in Clovis Oncology, Inc. Palo Alto Ltd Liability Corporation holds 9.64% or 3.80M shares in its portfolio. 183,693 are owned by Voloridge Inv Mgmt Limited Liability Company.

Since March 15, 2017, it had 0 insider purchases, and 3 selling transactions for $528,600 activity. The firm issued an outperform rating and a $85.00 price target on the biopharmaceutical company's stock. Endurant Capital Management Limited Partnership stated it has 0.34% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Therefore 79% are positive. Company stock is -21.16% away from its one year high and is moving 83.42% ahead of its one year low. They now have a $75.00 price objective on the biopharmaceutical company's stock.

05/01/2015 - Clovis Oncology, Inc. was upgraded to " by analysts at Zacks. Wells Fargo Mn holds 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 40,543 shares. They now have a United States dollars 23 price target on the stock. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has "Overweight" rating given on Thursday, January 26 by PiperJaffray. The firm has "Overweight" rating given on Friday, January 13 by Morgan Stanley.

On October 25, 2016 Chardan Capital initiated coverage on the stock with an initial rating of "Sell". WallachBeth Capital maintained Clovis Oncology Inc (NASDAQ:CLVS) rating on Monday, May 9. Ladenburg Thalmann Financial Services Inc. increased its stake in Clovis Oncology by 20.0% in the fourth quarter. The consensus recommendation by Thomson Reuters Analysts is Hold for KOPN and their mean rating for the stock is 3.00 on scale of 1-5.

In Georgia, a cacophony of arguments could tilt House race
The Atlanta Journal-Constitution newspaper reported that Ossoff's Republican opponent, Karen Handel , also condemned the ad. Georgia's 6th district encompasses much of suburban Atlanta and until recently was considered a shoe-in for Republicans.

A look at some of the inputs to technical analysis model shows how Clovis Oncology, Inc. current price compares to its recent moving averages. Finally, Credit Suisse Group boosted their price target on shares of Clovis Oncology from $53.00 to $70.00 and gave the stock an "outperform" rating in a research report on Thursday, February 23rd. The latest reports which are outstanding on Monday 19th of June state 3 analysts have a rating of "strong buy", 5 analysts "buy", 3 analysts "neutral", 1 analysts "sell" and 0 analysts "strong sell".

Investors wait Clovis Oncology Inc (NASDAQ:CLVS) to report on August, 14. its quarterly earnings Wall Street analysts expect $-1.37 EPS, up $0.70 or 33.82 % from last year's $-2.07 same quarter earnings.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. The company's market cap is $3.93 billion. Equities research analysts anticipate that Clovis Oncology will post ($4.95) earnings per share for the current fiscal year.

In December, Rubraca was granted accelerated approval by the U.S. Food and Drug Administration for patients whose tumors have a BRCA mutation and whose disease has continued to develop despite multiple rounds of chemotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.